# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce leukocyte migration
- describe integrin adhesion receptors
- explain integrin activation
- discuss β2 integrins
- describe I domain and MIDAS
- introduce ICAMs
- discuss LFA-1/ICAM-1 binding
- describe therapeutic benefits of inhibition
- introduce anti-integrin therapy
- discuss talin and Rap-1 signaling

## SUMMARY OF THE INVENTION

- introduce leukocyte-selective delivery agent
- describe targeting moiety
- describe protein carrier moiety
- describe therapeutic agent
- outline method for leukocyte-selective delivery

## DETAILED DESCRIPTION OF THE INVENTION

- introduce cell type specific delivery of an agent
- describe leukocyte-selective delivery agent
- outline components of delivery agent
- explain targeting moiety function
- describe methods for selective delivery
- discuss use of activated leukocyte selective delivery agent
- outline method to deliver therapeutics
- describe targeting agent
- explain activation-insensitive targeting moiety
- discuss conformational changes of integrins

### Targeting Agent

- define targeting agent
- list examples of targeting agents
- describe antibody as targeting agent
- explain functional fragments of antibodies
- discuss use of multiple targeting agents
- describe leukocyte targeting
- outline integrin molecules as targets
- explain activation-insensitive targeting moiety
- describe TS1/18 antibody
- discuss conformational changes of integrins
- explain selective delivery to active or inactive cells
- describe integrin conformation and ligand binding
- outline importance of integrins in leukocyte emigration
- discuss antibodies to leukocyte integrins
- explain I-domain of integrin α subunits
- describe metal ion-dependent adhesion site (MIDAS)
- outline structure of I-domain
- discuss ligand binding site of I-domain
- explain targeting moiety binding to active integrin
- describe targeting moiety binding to LFA-1 I-domain
- outline generation of targeting moieties
- discuss antibodies to open conformation of I-domain
- describe AL-57 antibody
- outline targeting moiety binding to β2 leg of LFA-1
- discuss KIM127 antibody
- explain epitopes unique to activated or inactivated integrins
- describe ICAM derived peptides as targeting moieties
- outline targeting moieties that inhibit ligand binding
- discuss targeting moieties that do not interfere with ligand binding

### Carriers for Therapeutic Agents

- introduce carrier particles
- define liposomes as carrier particles
- describe modification of liposome surface
- introduce long-circulating agents
- describe cryoprotectants
- introduce hyaluronic acid as cryoprotectant
- describe covalent attachment of cryoprotectant
- introduce crosslinking reagents
- describe covalent attachment of targeting moiety
- introduce micelles as carrier particles
- describe modification of micelle surface
- introduce unilamellar liposomes
- describe first layer of surface modification
- introduce second layer of surface modification
- describe encapsulation of therapeutic agent
- introduce nucleic acid therapeutic agents
- describe condensation of nucleic acid with cationic polymer
- introduce multi-layered liposomes
- describe lyophilization of liposomes
- introduce other cryoprotectants
- describe pre-conjugation of lipid particle with cryoprotectant
- introduce two-agent delivery
- describe association of hydrophobic agent with lipid particle
- introduce protein as carrier moiety
- describe nucleic acid binding domain of protein
- introduce complexing agents for nucleic acid
- describe cationic peptides as carrier moieties
- introduce protamine as carrier moiety
- describe functional fragments of protamine
- introduce nucleic acid sequences for protamine fragments
- describe full-length protamine as carrier moiety
- introduce chimeric protein carrier moieties
- describe glycosaminoglycan carrier particles
- introduce soluble polymers as carrier particles
- describe biodegradable polymers for controlled release
- introduce rigid polymers and other structures as carrier particles

### Therapeutic Agents

- define therapeutic agents
- describe nucleic acid therapeutic agents
- describe small molecule therapeutic agents
- describe polypeptide therapeutic agents
- describe antibody therapeutic agents
- describe functional fragments of therapeutic agents
- describe modification of therapeutic agents
- describe delivery of multiple therapeutic agents
- describe therapeutic agents targeting proinflammatory mediators
- describe therapeutic agents targeting enzymes involved in inflammatory mediators
- describe therapeutic agents targeting receptors for cytokines
- describe therapeutic agents targeting lipid mediators
- describe therapeutic agents targeting apoptosis
- describe therapeutic agents targeting cytoplasmic signaling molecules
- describe therapeutic agents targeting cell activation and proliferation
- describe therapeutic agents targeting cell movement/migration/invasion
- describe therapeutic agents targeting oncogenes
- describe specific targeting of CD4
- describe specific targeting of Ku70
- describe specific targeting of Cyclin-D1
- describe therapeutic agents for treating viral diseases
- describe siRNA as microbicides
- describe therapeutic agents for treating diseases such as HSV, HPB, and HIV
- describe small molecule therapeutic agents blocking intracellular signaling cascades
- describe therapeutic agents blocking enzymes
- describe therapeutic agents blocking proteosome
- describe therapeutic agents blocking lipid metabolism
- describe therapeutic agents blocking cell cycle
- describe therapeutic agents blocking membrane trafficking
- describe chemotherapy agents

### Methods

- describe methods for delivering therapeutic agents
- describe in vivo delivery
- describe in vitro delivery
- describe ex vivo delivery
- describe contacting targeting moiety to target cells
- describe preserving cell integrity
- describe promoting effective association of targeting moiety
- describe effective uptake of therapeutic agent
- describe routes of delivery
- describe subjects for therapy
- describe screening targets of pharmaceutical intervention
- describe measuring effects of targeted genes

## Targeted Delivery of siRNA to Activated Leukocytes via Antibody Selective to High-Affinity Form of Integrin LFA-1

- develop soluble designer LFA-1 I domains
- select phage library with locked high-affinity I domain
- examine clones by phage-ELISA
- identify clone #57 that binds to open I domain
- convert Fab to intact IgG
- show AL-57 binds to LFA-1 on cell surface
- inhibit LFA-1-ICAM-1 interaction
- prepare immuno-nanoparticles
- develop novel unilamellar liposomes with HA and antibodies
- show HA acts as cryoprotectant and long-circulating agent
- prepare lipids and multilamellar liposomes
- obtain unilamellar nano-scale liposomes by extrusion
- modify surface with HA and attach antibodies
- purify immuno-nanoparticles by gel filtration
- study size distribution and surface charge
- measure antibody attachment to nanoparticles
- encapsulate siRNAs to CD4, Ku70, and luciferase
- condense siRNAs with protamine or PEI
- quantify siRNA entrapment in nanoparticles
- study silencing in lymphocytes constitutively activated by agonists
- show AL-57-NP selectively silences CD4 expression
- study silencing in lymphocytes activated by physiologic inside-out signaling
- induce sustained activation of LFA-1
- show AL-57-NP silences CD4 expression in activated lymphocytes
- produce AL-57-protamine fusion protein
- express and purify fusion protein
- show binding of AL-57-PF to cell surface LFA-1
- study siRNA delivery by AL-57-PF
- show stoichiometry of siRNA binding to AL-57-PF
- study silencing by AL-57-PF in activated leukocytes
- show dose-dependent silencing of CD4 by AL-57-PF
- study silencing of Ku70 by AL-57-PF
- show silencing of Ku70 in activated lymphocytes
- study silencing in lymphocytes activated by physiologic inside-out signaling
- show AL-57-PF targets activated and persistently adherent leukocytes
- study inhibited proliferation of lymphocytes by cyclin-D1-siRNA
- show selective delivery of Cy3-siRNA by AL-57-PF
- study confocal microscopy of labeled fusion protein-siRNA complexes

## Example 2.1

### Gene Silencing by AL-57-NP In Vitro

- introduce rationale for gene silencing
- describe heterogeneous populations
- outline three sets of experiments
- introduce KIM127 as a complementary approach
- describe simultaneous fluorescent staining
- introduce methods
- describe isolation of CD4+ T-cells
- outline activation by CBRLFA-1/2
- describe co-culturing of cells
- introduce AL-57-, TS1/22-, or IgG-NPs
- describe IFC analysis
- outline activation by cross-linking of TCR Vβ3
- describe immobilization of mAb to TCR Vβ3
- introduce CD4-siRNA in AL-57-, TS1/22-, or IgG-NPs
- describe IFC analysis of CD4 expression
- outline delivery to lymphocytes, monocytes, and neutrophils
- describe activation of LFA-1 in whole blood samples
- introduce Ku70-siRNA in AL-57-, TS1/22-, and IgG1-NPs
- describe IFC analysis at 24, 48, and 60 hrs
- anticipate results for activation by CBRLFA-1/2
- discuss potential pitfalls for activation by CBRLFA-1/2
- anticipate results for activation by cross-linking TCR Vβ3
- discuss potential pitfalls for activation by cross-linking TCR Vβ3
- introduce IFN-response
- describe rationale for IFN-response
- outline quantitative RT-PCR
- anticipate results for IFN-response
- discuss potential pitfalls for IFN-response
- introduce impact on integrin function and signaling
- describe rationale for impact on integrin function and signaling
- outline adhesion assay and costimulatory activity
- anticipate results for impact on integrin function and signaling

### Example 2.2

- introduce NOD/Lt-scid IL2rγnull-hu-PBL model
- hypothesize biphasic activation of engrafted T-cells
- describe methods for studying LFA-1 activation
- introduce antibodies for identifying high-affinity LFA-1
- analyze activation status of LFA-1
- study expression of AL-57 and KIM127 epitopes
- correlate expression of AL-57 and KIM127 with CD25
- examine binding of AL-57-NP and AL-57-PF ex vivo
- study binding of AL-57-NP and AL-57-PF to hu CD45+ and TS2/4+ cells
- anticipate results of LFA-1 activation study
- discuss potential pitfalls of LFA-1 activation study
- introduce alternative approaches for LFA-1 activation study
- introduce biodistribution and pharmacokinetics of AL-57-NP
- study biodistribution of immuno-nanoparticles
- study biodistribution of protamine fusion proteins
- anticipate results of biodistribution study
- discuss potential pitfalls of biodistribution study
- introduce alternative approaches for biodistribution study
- introduce siRNA delivery and gene-silencing by AL-57-NP
- confirm binding of AL-57-NP and -PF ex vivo
- study in vivo binding of Cy3-labeled vehicles
- study delivery of Cy3-siRNAs formulated in AL-57-NP or -PF
- study in vivo gene silencing with Ku70-siRNAs
- anticipate results of siRNA delivery and gene-silencing study
- discuss potential pitfalls of siRNA delivery and gene-silencing study
- introduce alternative approaches for siRNA delivery and gene-silencing study
- study binding of Cy3-labeled protamine fusion proteins
- study delivery of Cy3-siRNAs by protamine fusion proteins
- study gene silencing with Ku70-siRNA by protamine fusion proteins
- discuss significance of results and potential pitfalls

## Discussion

### Integrin LFA-1 as Drug Delivery Target

- motivate LFA-1 as drug delivery target
- summarize LFA-1 expression in leukocytes
- describe LFA-1 internalization and recycling
- explain LFA-1 conformational changes
- discuss LFA-1-mediated internalization and lysosomal degradation
- introduce mAb AL-57 for selective targeting
- describe blocking of leukocyte adhesion by LFA-1 antibodies
- discuss combination of LFA-1 blocking with gene silencing
- motivate siRNA for gene silencing
- describe local delivery of siRNAs
- discuss cell-type- and tissue-specific delivery of siRNAs

### Targeted Delivery of Liposomes for Anti-Inflammatory Therapies

- introduce liposomes as drug carrier system
- describe drawbacks of early liposome use
- discuss modification of liposome surface with antibodies and ligands
- summarize applications of immuno-liposomes in inflammatory diseases
- discuss receptor-mediated internalization of immune-liposomes

### Example 3

- express LFA-1 fusion proteins
- convert IgG antibodies to scFvs
- fuse scFvs with protamine peptide
- express and purify AL-57-PF and TS1/22-PF
- verify binding specificity of AL-57-PF and TS1/22-PF
- test siRNA delivery by AL-57-PF and TS1/22-PF
- analyze Ku70 gene silencing by AL-57-PF and TS1/22-PF
- test CCR5 gene silencing by AL-57-PF and TS1/22-PF
- demonstrate selective siRNA delivery by AL-57-PF
- test Ku70 gene silencing in heterogeneous cell populations
- deliver siRNA to silence gene expression in lymphocytes
- activate lymphocytes by TCR or chemokine stimulation
- verify LFA-1 conformation change after stimulation
- test AL-57-PF-mediated knockdown of cyclin D1
- suppress proliferation selectively in activated lymphocytes
- test in vivo siRNA delivery by LFA-1-targeted fusion proteins
- inject fusion protein-siRNA complexes into SCID mice
- analyze siRNA delivery to K562 cells in lung tissues
- examine siRNA delivery to K562-WT LFA-1 and K562-HA LFA-1
- test TS1/22-PF-mediated siRNA delivery in vivo
- test AL-57-PF-mediated siRNA delivery in vivo
- examine siRNA delivery to mouse lung cells
- test siRNA delivery by control fusion protein ML39-PF
- examine lymphocyte activation by fusion protein-siRNA complexes
- measure CD25 and CD69 expression after treatment
- test IFN responses to fusion protein-siRNA complexes
- measure mRNA expression of IFN-β and IRG
- compare IFN responses to LPS and poly(I:C)
- discuss LFA-1-targeted scFv-protamine fusion proteins
- discuss advantages of selective gene silencing
- discuss potential therapeutic applications
- discuss other activation markers for selective targeting
- discuss in vivo studies for disease pathogenesis
- discuss RNAi-based therapy
- discuss systemic siRNA delivery to liver
- discuss in vivo siRNA delivery to other organs
- discuss in vivo siRNA delivery to moving targets
- discuss engineering murine analogs for in vivo testing
- discuss feasibility study using SCID mice
- discuss potential therapeutic approaches
- discuss combining LFA-1-blocking antibodies with gene silencing
- describe siRNA delivery and gene silencing
- detail T lymphocyte activation through CXCR4 and TCR
- outline mixed-population transduction experiment
- describe in vivo delivery
- construct and express scFv and scFv-protamine fusion proteins
- isolate and prepare PBMC and memory T lymphocytes
- prepare siRNAs
- transfect siRNAs
- perform quantitative RT-PCR
- assay lymphocyte proliferation
- perform flow cytometry
- acquire and process images
- perform immunohistochemistry
- reference list for example 3
- motivate siRNA delivery
- describe siRNA delivery methods
- detail siRNA delivery results
- discuss siRNA delivery implications
- motivate T lymphocyte activation
- describe T lymphocyte activation methods
- detail T lymphocyte activation results
- discuss T lymphocyte activation implications
- motivate mixed-population transduction
- describe mixed-population transduction methods
- detail mixed-population transduction results
- discuss mixed-population transduction implications

